LYMPHOID NEOPLASIA Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

نویسندگان

  • Yu-Tzu Tai
  • Betty Y. Chang
  • Sun-Young Kong
  • Mariateresa Fulciniti
  • Guang Yang
  • Yolanda Calle
  • Yiguo Hu
  • Jianhong Lin
  • Jian-Jun Zhao
  • Antonia Cagnetta
  • Michele Cea
  • Michael A. Sellitto
  • Mike Y. Zhong
  • Qiuju Wang
  • Chirag Acharya
  • Daniel R. Carrasco
  • Joseph J. Buggy
  • Laurence Elias
  • Steven P. Treon
  • William Matsui
  • Paul Richardson
  • Nikhil C. Munshi
  • Kenneth C. Anderson
چکیده

Yu-Tzu Tai,1 Betty Y. Chang,2 Sun-Young Kong,1,3 Mariateresa Fulciniti,1 Guang Yang,4 Yolanda Calle,5 Yiguo Hu,1 Jianhong Lin,1 Jian-Jun Zhao,1 Antonia Cagnetta,1 Michele Cea,1 Michael A. Sellitto,1 Mike Y. Zhong,1 Qiuju Wang,6 Chirag Acharya,1 Daniel R. Carrasco,1,7 Joseph J. Buggy,2 Laurence Elias,2 Steven P. Treon,4 William Matsui,6 Paul Richardson,1 Nikhil C. Munshi,1,8 and Kenneth C. Anderson1

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.

Bruton tyrosine kinase (Btk) has a well-defined role in B-cell development, whereas its expression in osteoclasts (OCs) further suggests a role in osteoclastogenesis. Here we investigated effects of PCI-32765, an oral and selective Btk inhibitor, on osteoclastogenesis as well as on multiple myeloma (MM) growth within the BM microenvironment. PCI-32765 blocked RANKL/M-CSF-induced phosphorylation...

متن کامل

Frequency of FLT3 ITD and FLT3 TKD Mutations in Multiple Myeloma Patients (A Case Control Study)

Background and Aims: Multiple myeloma is a malignant proliferation of plasma cells derived from a single clone. The tumor, its products and the host response lead to organ damages. Some factors that are responsible in its pathogenesis are recognized. As FMS like Tyrosine Kinase 3 receptor (FLT3) mutation has been proved as a determining factor in leukemic patients the goal of this study was to ...

متن کامل

Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment

Multiple myeloma is a plasma cell malignancy that homes aberrantly to bone causing extensive skeletal destruction. Despite the development of novel therapeutic agents that have significantly improved overall survival, multiple myeloma remains an incurable disease. Matrix metalloproteinase-2 (MMP-2) is associated with cancer and is significantly overexpressed in the bone marrow of myeloma patien...

متن کامل

Targeting the TAM Receptors in Leukemia

Targeted inhibition of members of the TAM (TYRO-3, AXL, MERTK) family of receptor tyrosine kinases has recently been investigated as a novel strategy for treatment of hematologic malignancies. The physiologic functions of the TAM receptors in innate immune control, natural killer (NK) cell differentiation, efferocytosis, clearance of apoptotic debris, and hemostasis have previously been describ...

متن کامل

LYMPHOID NEOPLASIA Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation

Adhesive interactions between multiple myeloma (MM) cells and marrow stromal cells activate multiple signaling pathways including nuclear factor B (NFB), p38 mitogen-activated protein kinase (MAPK), and Jun N-terminal kinase (JNK) in stromal cells, which promote tumor growth and bone destruction. Sequestosome-1 (p62), an adapter protein that has no intrinsic enzymatic activity, serves as a plat...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2012